Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04792684

Collection of Samples USOPTIVAL Study

A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–84 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Precision Recearch Institute, Chula Vista, California, United States

Loading trial locations.

About this study

This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination.

Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Arm A:

  • Must be 45-84 years of age.
  • Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
  • Able to comprehend, sign, and date the written informed consent document.

Arm B:

  • Must be 45-84 years of age.
  • Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
  • Able to comprehend, sign, and date the written informed consent document.

Exclusion criteria

Arm A Only:

  • Subject with curative biopsy during colonoscopy.

Arm B Only:

  • Subjects with positive FIT Test results in the 6 months preceding enrollment.
  • Subject has a current diagnosis of cancer.

Arms A & B:

  • Subject has a personal history of aerodigestive or digestive tract cancers.
  • Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
  • Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:
  • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
  • Familial adenomatous polyposis ("FAP", including attenuated FAP).
  • Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
  • Serrated polyposis syndrome
  • 2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
  • One first-degree relative with CRC diagnosed before the age of 60.
  • A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
  • Legal incapacity or limited mental capacity.
  • Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
  • The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
  • The patient is known to be pregnant when recruited or during her participation in the study.

Treatment and study plan

Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel

Diagnostic Test

Evaluate the performance of a preliminary panel of biomarkers

Primary outcomes

  1. Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing

    Time frame: Within 12 months of sample collection

    Samples Collected for Testing

Study contacts

Contact information is provided by the study sponsor or research team.

Antonio Jesus Merino Calvo

CONTACT

[email protected]

(+34)674945571

Sponsors and collaborators

Lead sponsor

Universal Diagnostics

Industry

Registry information

Official study title

Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Mar 11, 2021
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.